Another ongoing phase 1 clinical trial (NCT04189614) is further investigating the effectiveness and safety of cofetuzumab pelidotin in patients with recurring PTK7+ NSCLC. This evidence concerns the gene PTK7 and non-small cell lung carcinoma.